Learn more

JANSSEN PHARMACEUTICA NV

Overview
  • Total Patents
    21,250
  • GoodIP Patent Rank
    466
  • Filing trend
    ⇩ 48.0%
About

JANSSEN PHARMACEUTICA NV has a total of 21,250 patent applications. It decreased the IP activity by 48.0%. Its first patent ever was published in 1958. It filed its patents most often in United States, EPO (European Patent Office) and Australia. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are SUGEN, REMYND NV and BANYU PHARMA CO LTD.

Patent filings in countries

World map showing JANSSEN PHARMACEUTICA NVs patent filings in countries
# Country Total Patents
#1 United States 1,756
#2 EPO (European Patent Office) 1,591
#3 Australia 1,476
#4 WIPO (World Intellectual Property Organization) 1,456
#5 Canada 1,372
#6 China 1,142
#7 Israel 935
#8 Republic of Korea 735
#9 Brazil 677
#10 South Africa 652
#11 New Zealand 611
#12 Taiwan 583
#13 Norway 563
#14 Argentina 532
#15 Mexico 507
#16 Hong Kong 421
#17 Hungary 355
#18 EAPO (Eurasian Patent Organization) 324
#19 Japan 272
#20 Poland 252
#21 Ukraine 227
#22 Malaysia 207
#23 Singapore 195
#24 Chile 194
#25 Finland 193
#26 Philippines 162
#27 Peru 160
#28 Czechia 156
#29 Costa Rica 150
#30 Denmark 144
#31 Ireland 139
#32 Bulgaria 138
#33 Slovakia 136
#34 Portugal 134
#35 Croatia 131
#36 Uruguay 123
#37 United Kingdom 122
#38 Ecuador 118
#39 Serbia 117
#40 Colombia 113
#41 Spain 113
#42 Jordan 108
#43 Nicaragua 90
#44 Estonia 89
#45 Russian Federation 87
#46 Germany 85
#47 African Regional Industrial Property Organization 79
#48 Cyprus 71
#49 Greece 70
#50 USSR (Union of Socialist Soviet Republics) 69
#51 Montenegro 67
#52 Morocco 66
#53 France 65
#54 Panama 56
#55 Netherlands 55
#56 Switzerland 52
#57 Indonesia 52
#58 Romania 50
#59 Austria 46
#60 Sweden 46
#61 Yugoslavia (Serbia and Montenegro) 44
#62 Czechoslovakia 41
#63 African Intellectual Property Organization 37
#64 Latvia 34
#65 Slovenia 33
#66 Zimbabwe 33
#67 Italy 31
#68 Belgium 30
#69 El Salvador 30
#70 Egypt 29
#71 Tunisia 28
#72 Zambia 28
#73 India 22
#74 Iceland 21
#75 Lithuania 19
#76 Luxembourg 17
#77 Turkey 16
#78 Honduras 13
#79 Kenya 12
#80 Dominican Republic 9
#81 Algeria 8
#82 Guatemala 8
#83 Saudi Arabia 8
#84 German Democratic Republic 7
#85 Bosnia and Herzegovina 2
#86 Georgia 2
#87 Gulf Cooperation Council 1

Patent filings per year

Chart showing JANSSEN PHARMACEUTICA NVs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Heeres Jan 808
#2 Meerpoel Lieven 671
#3 Janssens Frans Eduard 642
#4 Freyne Eddy Jean Edgard 435
#5 Sui Zhihua 391
#6 Kennis Ludo Edmond Josephine 384
#7 Janssen Paul Adriaan Jan 380
#8 Angibaud Patrick Rene 358
#9 Venet Marc Gaston 350
#10 Edwards James P 345

Latest patents

Publication Filing date Title
WO2021069671A1 HEXAHYDRO-5,8-EPOXYCYCLOHEPTA[c]PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE CB1 AND/OR CB2 RECEPTORS
WO2021064569A1 Radiolabelled mgl pet ligands
WO2021058798A1 Use of fgfr inhibitors in fgfr-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings
WO2021023843A1 Improved synthetic methods of making (2h-1,2,3-triazol-2-yl)phenyl compounds as orexin receptor modulators
WO2021018948A1 Quinazolin-4-one derivatives useful as grk2 inhibitors
WO2021018951A1 Phthalazin-1-one derivatives useful as grk2 inhibitors
WO2021018118A1 Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 1 proteins
WO2021013742A1 5,8-disubstituted-[1,2,4]triazolo[1,5-a]pyridinyl and 5,8-disubstituted-imidazo[1,2-a]pyridine derivatives useful as inhibitors of enteropeptidase
WO2021009081A1 Binding agents and uses thereof
WO2021005043A1 Macrocyclic spirocycle derivatives as mcl-1 inhibitors
WO2020260499A1 Biorelevant dissolution media
WO2020254471A1 Macrocyclic inhibitors of mcl-1
US2020392154A1 Pyridine carbamates and their use as glun2b receptor modulators
US2020392130A1 SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
WO2020249796A1 Pyrazine carbamates and their use as glun2b receptor modulators
US2021017168A1 Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
US2020392113A1 Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators
WO2020249785A1 Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
WO2020249663A1 Novel spirobicyclic intermediates
WO2020245365A1 Methods of treating cancer using prmt5 inhibitors